Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coeptis Therapeutics Holdings (COEP) Return on Sales (2021 - 2025)

Coeptis Therapeutics Holdings (COEP) has 3 years of Return on Sales data on record, last reported at 12.21% in Q3 2025.

  • For Q3 2025, Return on Sales changed N/A year-over-year to 12.21%; the TTM value through Sep 2025 reached 27.28%, changed N/A, while the annual FY2021 figure was 179.32%, N/A changed from the prior year.
  • Return on Sales reached 12.21% in Q3 2025 per COEP's latest filing, up from 21.6% in the prior quarter.
  • Across five years, Return on Sales topped out at 3.46% in Q2 2022 and bottomed at 54.41% in Q1 2025.
  • Average Return on Sales over 3 years is 8.73%, with a median of 0.1% recorded in 2021.
  • The widest YoY moves for Return on Sales: up 336bps in 2022, down 292bps in 2022.
  • A 3-year view of Return on Sales shows it stood at 0.82% in 2021, then soared by 254bps to 2.9% in 2022, then plummeted by -521bps to 12.21% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Sales were 12.21% in Q3 2025, 21.6% in Q2 2025, and 54.41% in Q1 2025.